PARP inhibitors enhance antitumor immune responses by triggering pyroptosis via TNF–caspase 8–GSDMD/E axis in ovarian cancerYu Xia, Pu Huang, Yi-yu Qian, Zanhong Wang, Ning Jin, Xin Li, Wen Pan, Si-Yuan Wang, Ping Jin, Emmanuel Kwateng Drokow, Xiong Li, Qi Zhang, Zhengmao Zhang, Pingfei Li, Yong FangSee the full list of authors
4 October 2024
Gal-3 blocks the binding between PD-1 and pembrolizumabStinne Ravn Greisen, Mia Bendix, Morten Aagaard Nielsen, Kathrine Pedersen, Nina Haunstrup Jensen, Malene Hvid, Jakob Hauge Mikkelsen, Taner Drace, Thomas Boesen, Torben Steiniche, Henrik Schmidt, Bent Deleuran
2 October 2024
Cancer cell-specific PD-L1 expression is a predictor of poor outcome in patients with locally advanced oral cavity squamous cell carcinomaMinyu Wang, Lei Qin, Kevin Thia, Thu Nguyen, Sean MacDonald, Simone Belobrov, Sevastjan Kranz, David Goode, Joseph A Trapani, David Wiesenfeld, Paul Joseph Neeson
2 October 2024
Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE studyIdris Bahce, Chris Dickhoff, Famke L Schneiders, Joris Veltman, David J Heineman, Sayed M S Hashemi, Anne Vrijmoet, Ilias Houda, Ezgi B Ulas, Joyce Bakker, Peter van de Ven, Natalja Bouwhuis, Lilian J Meijboom, Daniela E Oprea-Lager, Febe van MaldegemSee the full list of authors
30 September 2024
Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumorsYoung Kwang Chae, Megan Othus, Sandip Patel, Benjamin Powers, Chung-Tsen Hsueh, Rangaswamy Govindarajan, Silvana Bucur, Hye Sung Kim, Liam IL-Young Chung, Christine McLeod, Helen X Chen, Elad Sharon, Howard Streicher, Christopher W Ryan, Charles BlankeSee the full list of authors
28 September 2024
MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumorsSi Chen, Jiakai Hou, Roshni Jaffery, Ashley Guerrero, Rongjie Fu, Leilei Shi, Ningbo Zheng, Ritu Bohat, Nicholas A Egan, Chengtai Yu, Sana Sharif, Yue Lu, Wei He, Shuyue Wang, Donjeta GjukaSee the full list of authors
23 September 2024
MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagersIñaki Eguren-Santamaria, Eva Fernández de Piérola, Gracián Camps, Paula Martín-Muñoz, María Campos, Doina Cuculescu, Inmaculada Aguilera-Buenosvinos, Inmaculada Rodríguez López, Rafael Salido-Vallejo, Raluca Alexandru, Carlos E De Andrea, Laura Álvarez-Gigli, Pedro Berraondo, Ignacio Melero, Miguel F Sanmamed
6 September 2024
Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinomaTanya Ramadoss, Matthew Nichols, Christian Palacios, Zeynep Eroglu, Joseph Markowitz, Lilit Karapetyan, Ahmad A Tarhini, Evan J Wuthrick, Vernon K Sondak, Nikhil I Khushalani, Kenneth Y Tsai, Andrew S Brohl
5 September 2024
Immune isolation-enabled nanoencapsulation of donor T cells: a promising strategy for mitigating GVHD and treating AML in preclinical modelsDan Mei, Ziyang Xue, Tianjing Zhang, Yining Yang, Lin Jin, Qianqian Yu, Jian Hong, Xianzheng Zhang, Jinru Ge, Li Xu, Han Wang, Ziwei Zhang, Yuchen Zhao, Yuanfang Zhai, Qianshan TaoSee the full list of authors
5 September 2024
Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapyYanyang Nan, Yu Bai, Xiaozhi Hu, Kaicheng Zhou, Tao Wu, An Zhu, Mengyang Li, Zihan Dou, Zhonglian Cao, Xumeng Zhang, Shuwen Xu, Yuanzhen Zhang, Jun Lin, Xian Zeng, Jiajun FanSee the full list of authors
3 September 2024